These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30825345)

  • 21. Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy.
    Sun L; Xu T; Yuan X; Liu F; Guan F; Ye D; Zhang G
    Tumori; 2020 Apr; 106(2):133-138. PubMed ID: 31451070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant hormonal therapy in carcinoma of the prostate.
    Lee HH; Warde P; Jewett MA
    BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
    Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
    J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
    Naiki T; Kawai N; Okamura T; Nagata D; Kojima Y; Akita H; Yasui T; Tozawa K; Kohri K
    BMC Urol; 2012 Dec; 12():36. PubMed ID: 23249358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.
    Kitagawa Y; Koshida K; Mizokami A; Komatsu K; Nakashima S; Misaki T; Katsumi T; Namiki M
    Int J Urol; 2003 Jul; 10(7):377-82. PubMed ID: 12823692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
    Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
    Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F; Goldenberg SL; Klotz LH
    J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
    Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
    Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Urol Int; 1998; 60 Suppl 2():11-7; discussion 35. PubMed ID: 9607553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
    Downes MR; Satturwar S; Trudel D; van der Kwast TH
    Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy.
    Yasuda M; Shimizu M; Fujita M; Miyazawa M; Tang X; Kajiwara H; Osamura RY; Shoji S; Tokunaga M; Terachi T
    Cancer Detect Prev; 2007; 31(5):396-401. PubMed ID: 18031949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.